What Is a Peptide and Why Does Delivery Matter?

A peptide is a short chain of amino acids linked by peptide bonds. The human body uses thousands of them as signaling molecules, hormones, and structural components. Researchers are interested in synthetic or isolated peptides because they can, in theory, mimic or modulate those natural signals with a high degree of specificity.

The delivery question matters because a compound that never reaches its target tissue in an active form cannot produce a measurable effect. Pharmacokinetics, the study of how a substance moves through the body, covers four stages: absorption, distribution, metabolism, and excretion. For peptides, the absorption and metabolism stages are where most of the problems arise. A peptide that looks promising in a cell culture dish may behave very differently once it encounters the full biochemical environment of a living organism.

Researchers choose a delivery route based on what they need to measure. If the goal is to study a peptide's effect on a specific tissue or receptor, they need enough of the compound to arrive there intact. The route of administration is therefore a methodological choice, not an arbitrary one, and it shapes every downstream conclusion the study can draw.

Why Does Oral Delivery Fail for Most Peptides?

The gastrointestinal tract is extraordinarily efficient at breaking down proteins and peptides. Proteolytic enzymes, including pepsin in the stomach and a family of proteases secreted by the pancreas, are designed to cleave peptide bonds. That process is essential for nutrition: it converts dietary protein into individual amino acids the body can absorb. The problem is that those same enzymes do not distinguish between a piece of chicken and a therapeutic peptide.

Even peptides that survive the stomach and small intestine face a second barrier called first-pass metabolism. Blood from the intestinal wall drains into the portal vein and passes through the liver before entering systemic circulation. Hepatic enzymes, particularly peptidases and cytochrome P450 enzymes, can further degrade or modify the compound. The fraction of an orally administered drug that actually reaches systemic circulation unchanged is called oral bioavailability. For most unmodified peptides, that number is very low, often below five percent, and sometimes effectively zero.

Researchers have documented this problem extensively. A 2017 review published in the Journal of Controlled Release noted that the oral bioavailability of peptide drugs is typically less than two percent without chemical modification or specialized delivery systems. That figure explains why the pharmaceutical industry has invested heavily in technologies like enteric coatings, nanoparticle carriers, and permeation enhancers, but most of those approaches are still in early development for research peptides specifically.

The Case for Subcutaneous and Intramuscular Routes

Subcutaneous injection deposits a compound into the layer of fat and connective tissue just beneath the skin. From there, the compound diffuses into nearby capillaries and enters systemic circulation without passing through the liver first. Intramuscular injection places the compound directly into muscle tissue, which is densely vascularized and absorbs many compounds quickly. Both routes bypass the gastrointestinal tract entirely, which is precisely why researchers favor them for peptides.

Bioavailability via subcutaneous injection is substantially higher than oral bioavailability for most peptides. For some well-studied compounds, subcutaneous bioavailability approaches 70 to 90 percent. That predictability is scientifically valuable: when a researcher knows how much of a compound reached circulation, they can draw cleaner conclusions about dose-response relationships and mechanism of action.

The pharmacokinetic profiles also differ in useful ways. Subcutaneous injection tends to produce a slower, more sustained release compared to intravenous administration, because the compound must first diffuse out of the injection site. Intramuscular injection generally produces faster absorption than subcutaneous because muscle tissue has a richer blood supply. Researchers select between these routes depending on whether they want a rapid peak concentration or a more gradual systemic exposure, and both choices are documented clearly in published study methods.

How Molecular Size and Structure Affect the Choice

Peptide size is measured in daltons (Da), a unit of molecular mass. Smaller peptides, those with two to five amino acids, are sometimes absorbed orally to a limited degree, particularly if they share structural similarity with di- or tripeptides that the gut transports via specific carrier proteins. Larger peptides, generally above 500 to 1000 Da, have almost no practical oral bioavailability without significant formulation engineering.

Structure matters too. Peptides with a high proportion of hydrophilic (water-attracting) amino acids do not cross lipid-based cell membranes easily, which limits their ability to penetrate the intestinal wall. Cyclic peptides, where the chain forms a ring rather than a straight line, are generally more resistant to enzymatic degradation because their shape makes it harder for proteases to access the peptide bonds. Some research compounds are specifically designed with cyclic structures or non-natural amino acids to improve stability, but even these often require parenteral delivery in research settings to achieve reliable systemic exposure.

Half-life is another relevant variable. Many peptides are cleared from circulation within minutes to a few hours. Researchers designing studies must account for this by selecting a delivery route that produces a measurable window of activity. Subcutaneous injection often extends that window compared to intravenous delivery because the absorption phase itself slows the overall kinetic curve, a property that can be useful when studying effects that take time to manifest.

What This Means for Interpreting the Research Record

A large portion of peptide research is preclinical, meaning it was conducted in cell cultures or animal models rather than in human clinical trials. When reading a study, the delivery route used in that study is the only context in which the findings apply. A peptide shown to have a particular effect in rats given subcutaneous injections has not been shown to have that effect in humans taking an oral supplement. Those are different experiments with different compounds, different species, and different pharmacokinetic profiles.

Human clinical trials for peptide compounds are relatively rare compared to the volume of preclinical literature. Where human trials do exist, they almost always use parenteral delivery for the reasons described above. Semaglutide, the active molecule in the FDA-approved drugs Ozempic and Wegovy, is a GLP-1 receptor agonist peptide that was originally studied and approved in injectable form. An oral version, Rybelsus, required a specialized absorption enhancer called SNAC to achieve meaningful bioavailability, and its development took years of additional research. Research-chemical versions of semaglutide are not FDA-approved in any form.

For readers evaluating claims about peptide products, the delivery route listed in a cited study is a quick quality check. If a study used injections and a product is sold as an oral supplement, the study does not directly support the product's efficacy. That gap is not a minor technicality; it reflects a fundamental difference in how much active compound reaches the body's tissues. Anyone with clinical questions about peptide therapies should consult a licensed healthcare provider who can evaluate individual circumstances and current evidence.

Frequently asked questions

Are there any peptides that work orally without special formulation?

A small number of short peptides, particularly di- and tripeptides, can be absorbed through intestinal carrier proteins to some degree. Collagen-derived dipeptides like Pro-Hyp have been detected in human blood after oral ingestion in studies such as Iwai et al. (2005) in the Journal of Agricultural and Food Chemistry. However, most research peptides of interest, including growth hormone secretagogues, tissue repair peptides, and melanocortin peptides, are longer chains that do not survive the gastrointestinal environment in meaningful quantities without chemical modification or specialized delivery technology.

Does the injection route used in a study affect how we should interpret the results?

Yes, significantly. The route of administration determines how much of a compound reaches systemic circulation and at what concentration. A finding from a study using intravenous injection, which delivers 100 percent of the dose directly to the bloodstream, cannot be directly compared to a subcutaneous study or an oral study. Bioavailability, peak concentration, and the time course of exposure all differ by route. When evaluating any peptide study, noting the administration method in the methods section is a basic step in assessing whether the results are relevant to a different delivery context.

Why do some peptide drugs have both injectable and oral forms if oral delivery is so difficult?

Developing an oral form of a peptide drug typically requires years of additional pharmaceutical engineering beyond proving the injectable version works. The oral semaglutide tablet (Rybelsus) uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, known as SNAC, as an absorption enhancer that temporarily increases permeability in the stomach lining. Even with that technology, the oral bioavailability of semaglutide is roughly one percent compared to the subcutaneous form, which is why the oral dose used in trials was substantially higher. These formulation solutions are compound-specific and cannot be generalized to other peptides without independent research.

Sources

  1. Drucker, D.J., 2020, Nature Reviews Drug Discovery, GLP-1 peptide pharmacology Covers peptide drug delivery and bioavailability challenges
  2. Muheem et al., 2016, Saudi Pharmaceutical Journal, oral peptide delivery strategies Reviews enzymatic barriers to oral peptide absorption
  3. Iwai et al., 2005, Journal of Agricultural and Food Chemistry, collagen dipeptide oral absorption Human evidence for oral absorption of short collagen peptides
  4. Antosova et al., 2009, Trends in Biotechnology, therapeutic peptide delivery overview Summarizes parenteral vs oral routes for peptide therapeutics

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.